Incyte Corporation (LON:0J9P)
 90.63
 -1.83 (-1.98%)
  At close: Oct 29, 2025
Incyte Revenue
Incyte had revenue of $1.37B USD in the quarter ending September 30, 2025, with 20.05% growth. This brings the company's revenue in the last twelve months to $4.81B, up 18.09% year-over-year. In the year 2024, Incyte had annual revenue of $4.24B with 14.76% growth.
Revenue (ttm) 
 $4.81B
Revenue Growth 
 +18.09%
P/S Ratio 
 3.72
Revenue / Employee 
 $1.84M
Employees 
 2,617
Market Cap 
13.30B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 4.24B | 545.57M | 14.76% | 
| Dec 31, 2023 | 3.70B | 301.01M | 8.87% | 
| Dec 31, 2022 | 3.39B | 408.37M | 13.67% | 
| Dec 31, 2021 | 2.99B | 319.57M | 11.98% | 
| Dec 31, 2020 | 2.67B | 507.94M | 23.53% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| AstraZeneca | 41.24B | 
| GSK plc | 31.63B | 
| Haleon | 11.02B | 
| Smith & Nephew | 4.33B | 
| Hikma Pharmaceuticals | 2.35B | 
| ConvaTec Group | 1.72B | 
| Spire Healthcare Group | 1.55B | 
| Genus | 672.80M | 
Incyte News
- 3 days ago - Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System - Business Wire
- 5 days ago - Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis - Business Wire
- 6 days ago - Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial - PRNewsWire
- 8 days ago - Incyte: Strong Growth, Margin Expansion, And Low Valuation - Seeking Alpha
- 10 days ago - Incyte Corporation (INCY) Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic Cancer Transcript - Seeking Alpha
- 11 days ago - Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma - Business Wire
- 14 days ago - Notable Thursday Option Activity: PYPL, HPE, INCY - Nasdaq
- 15 days ago - 3 Biotech Stocks I Am Accumulating - Seeking Alpha